Talk:Skycovione
This is the talk page for discussing improvements to the Skycovione article. This is not a forum for general discussion of the article's subject. |
Article policies
|
Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||||||
|
[edit]
"Skycovion is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine, in combination of GSK’s pandemic adjuvant".
91.159.191.87 (talk) 18:33, 8 March 2023 (UTC)
Categories:
- Articles with conflicting quality ratings
- Stub-Class COVID-19 articles
- Low-importance COVID-19 articles
- WikiProject COVID-19 articles
- Start-Class medicine articles
- Low-importance medicine articles
- All WikiProject Medicine articles
- Start-Class pharmacology articles
- Low-importance pharmacology articles
- WikiProject Pharmacology articles
- Start-Class Korea-related articles
- Low-importance Korea-related articles
- WikiProject Korea articles